Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Santarus Says FDA Accepts Application Seeking Approval For Colon Drug Uceris

Biopharmaceutical company Santarus, Inc. (SNTS: Quote) on Wednesday said the United States Food and Drug Administration has accepted for filing its new drug application for Uceris tablets indicated for treatment of inflammatory bowel disease.

With the application, or NDA, the company seeks approval to market Uceris (budesonide) tablets 9 mg in the U.S. as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review or a response to the NDA by mid-October 2012.

Santarus will now pay $4 million to the co-developer of the drug, Cosmo Technologies Limited, a unit of Japan's Cosmo Pharmaceuticals S.p.A, in cash or Santarus stock at Cosmo's option.

Ulcerative colitis is a form of inflammatory bowel disease that produces inflammation and ulcers along the inside of the colon that could cause cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements. According to the Crohn's & Colitis Foundation of America, the chronic relapsing-remitting illness affects an estimated 1.4 million Americans.

Gerald Proehl, president and chief executive officer, stated, "Ulcerative colitis is a serious, chronic disease that typically starts to manifest in young adults with a long-term negative impact on the patient. We look forward to the potential to offer what we believe will be an important new therapeutic option to physicians and their patients to manage the symptoms of active ulcerative colitis."

Santarus shares closed Tuesday's regular trading session at $4.80, down $0.12 or 2.44 percent.

Register
To receive FREE breaking news email alerts for Santarus Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Philippine economy grew more-than-expected in the second quarter on strong support from foreign demand, figures from the National Statistical Coordination Board showed Thursday. Gross domestic product for the second quarter advanced 6.4 percent year-on-year, exceeding economists' expectation for 6.1 percent growth. This followed by a revised 5.6 percent rise seen in the first quarter. Hewlett-Packard has recalled the AC power cords for its HP and Compaq notebook computer, citing a tendency to overheat, causing a potential fire and burn hazard. HP requests that consumers stop using the cord immediately and contact them to order a replacement cord free of charge. A UN report describing terrible atrocities carried out by Islamic State militants in Syria says children as young as 10 are being recruited and trained at ISIS camps as fighters. The report, based on 480 interviews and and evidence collected between 20 January and 15 July, chronicles the unimaginable brutality and human cost of the Syrian conflict. The report by the independent international com
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.